Pharma And Building Trust In The Healthcare Ecosystem
Executive Summary
Biopharma and legal experts discuss at a recent summit the need for multi-stakeholder action to foster trust across the healthcare system. Capital is going to flow away from unethical organizations, one executive predicted.
You may also be interested in...
Finance Watch: Investors Remain Receptive To Biopharma, Health Care SPAC IPOs
Public Company Edition: 2020 started with two $200m-plus initial public offerings plus five health care-focused special purpose acquisition corporations IPOs. Also, a Pfizer initiative backs three public companies, Fate’s $432m offering led recent FOPOs and Biocon Biologics receives more investment.
Six Questions For Sun Pharma MD Shanghvi
Sun Pharma’s founder and MD shares with Scrip his views on some key big picture issues, including leveraging pandemic-related regulatory experience for urgently needed products, expectations in the US market, the outlook for M&A, and the potential of e-pharmacies in India.
With US Respiratory Pipeline Unlocked, Cipla Wants Lung Leadership
Cipla sees an incremental revenue opportunity of up to $500m for its US franchise by fiscal 2025 and expects to propel growth with strong execution of its complex generics pipeline. The company is also beginning to “lay the blueprint” in China and Brazil, it said at the J.P. Morgan Healthcare Conference.
Need a specific report? 1000+ reports available
Buy Reports